Quantcast

Latest Phenols Stories

2014-10-23 16:25:56

Entrenchment of Current Analgesics and Increasing Cost Sensitivity Will Hamper Uptake of Emerging Acute Pain Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct. 23, 2014 /PRNewswire/ -- Decision Resources Group finds that the acute pain market will grow minimally from $12.7 billion in 2013 to $13.3 billion in 2023 across the major pharmaceutical markets (United States, France, Germany, Italy, Spain, the United Kingdom and Japan), representing an annual...

2014-10-23 12:29:10

FORT LAUDERDALE, Fla., Oct. 23, 2014 /PRNewswire/ -- Fort Lauderdale, Fla.-based Life Extension Foundation, a pioneer in supporting the latest integrative therapies and anti-aging research, provided product support for a study in conjunction with the IMIM-Hospital del Mar Research Institute, Barcelona, Spain. The resultant publication entitled, "Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans" was published in the...

2014-10-23 12:23:49

ROME, Oct. 23, 2014 /PRNewswire-USNewswire/ -- The U.S. government is opposing international efforts to halt the global use of a toxic chemical, pentachlorophenol (PCP), used in the U.S. on wood utility poles, at the same time as a bipartisan group of New York state lawmakers are seeking a state ban, and a lawsuit, filed by a group of Long Island residents, charges that hundreds of new PCP-treated utility poles are causing serious injury to health and property values. This month, the...

2014-10-22 08:32:56

Pain Insights, Inc. releases a comprehensive market research study on the impact of hydrocodone rescheduling, Zohydro(TM) ER, and abuse-deterrent formulations on prescribers and the pain market. FAIRFIELD, N.J., Oct. 22, 2014 /PRNewswire/ -- Rescheduling of hydrocodone combination products (HCPs) will impel a major transformation in the pain market, according to a new primary market research study by Pain Insights, Inc., a firm providing market research and consultation exclusively in the...

2014-10-21 08:33:43

Company's new identity to reflect its enhanced focus in chronic diseases of addiction RICHMOND, Va., Oct. 21, 2014 /PRNewswire/ -- Reckitt Benckiser Pharmaceuticals Inc. (RBP) today announced its UK-based parent company, Reckitt Benckiser Group plc (RB), expects the proposed demerger of the RBP business to complete in 2014. Reckitt Benckiser originally announced plans to demerge the RBP business in late July 2014, and the operational and financial separations, appointment of the new...

2014-10-16 08:31:24

Additional Capital Enable Company to Achieve Additional Milestones in its Business Plan NEW YORK, Oct. 16, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014. The warrants...

2014-10-10 12:24:40

RALEIGH, N.C., Oct. 10, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) (NASDAQ: BDSI) announced that J. Chris Prue, RPh, MBA has joined BDSI as Vice President of Regulatory Affairs and Quality Assurance. Mr. Prue brings more than 30 years of pharmaceutical industry experience in regulatory affairs and quality assurance to BDSI. He has held positions of increasing responsibility at The Upjohn Company, Glaxo Inc., GlaxoWellcome and Purdue Pharma LP. Recently...

2014-10-10 12:21:11

DUBLIN, Oct. 10, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global and Chinese 4,4-Biphenol Industry Report 2014" report to their offering. http://photos.prnewswire.com/prnvar/20130307/600769 The Global and Chinese 4,4-Biphenol Industry Report is a professional and in-depth study on the current state of the global 4,4-Biphenol industry with a focus on the Chinese situation. The report provides a basic overview of the industry including definitions,...

2014-10-09 08:28:41

Butrans® is now available for prescribing in five dosage strengths STAMFORD, Conn., Oct. 9, 2014 /PRNewswire/ -- Purdue Pharma L.P. announced the U.S. commercial launch of the new 7.5 mcg/hour dosage strength of Butrans(®) (buprenorphine) Transdermal System CIII. Five strengths of Butrans are now available: 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour and 20 mcg/hour. http://photos.prnewswire.com/prnvar/20100921/NY67262 Butrans is the first transdermal system that delivers seven days...

2014-10-08 08:26:47

RIDGEFIELD, Conn., Oct. 8, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that Striverdi® Respimat® (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States. STRIVERDI RESPIMAT is a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. STRIVERDI RESPIMAT is not indicated to treat asthma...


Word of the Day
conjunto
  • A style of popular dance music originating along the border between Texas and Mexico, characterized by the use of accordion, drums, and 12-string bass guitar and traditionally based on polka, waltz, and bolero rhythms.
The word 'conjunto' comes through Spanish, from Latin coniūnctus, past participle of coniungere, to join together; see conjoin